According to the standard clinical protocol, BRAF V600E IHC or quantitative polymerase chain reaction was performed in MLH1-deficient colorectal tumors before or at the time of referral to exclude likely sporadic cancers. The gene discussed is BRAF; the disease is colorectal neoplasm.